Evidence map›Paper›PMID 39614398›Full record

Observational studyJournal of health, population, and nutrition2024

Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal study.

Margaret Lartey, Ernest Kenu, Vincent Ganu, Stephen Ayisi Addo, Kofi Agyabeng, Delia Bandoh, Marijanatu Abdulai, Prince Tsekpetse, Kwasi Torpey

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of health, population, and nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Margaret LarteyDepartment of Medicine & Therapeutics, University of Ghana Medical School, Accra, Ghana.
Ernest KenuGhana Field Epidemiology and Laboratory Training Programme, Department of Epidemiology and Disease Control, School of Public Health, University of Ghana, Accra, Ghana.
Vincent GanuDepartment of Medicine, Korle Bu Teaching Hospital, Accra, Ghana. vincentjganu@gmail.com.
Stephen Ayisi AddoNational AIDS/STI Control Programme, Ghana Health Service, Accra, Ghana.
Kofi AgyabengDepartment of Biostatistics, School of Public Health, University of Ghana, Accra, Ghana.
Delia BandohGhana Field Epidemiology and Laboratory Training Programme, Department of Epidemiology and Disease Control, School of Public Health, University of Ghana, Accra, Ghana.
Marijanatu AbdulaiNational AIDS/STI Control Programme, Ghana Health Service, Accra, Ghana.
Prince TsekpetseGhana Field Epidemiology and Laboratory Training Programme, Department of Epidemiology and Disease Control, School of Public Health, University of Ghana, Accra, Ghana.
Kwasi TorpeyDepartment of Population, Family, Reproductive Health, School of Public Health, University of Ghana, Accra, Ghana.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFew studies have reported hyperglycemia and diabetic ketoacidosis in patients on dolutegravir (DTG) treatment. This study determined the effect of DTG on fasting blood glucose levels in a cohort of persons living with HIV (PLHIV) in Ghana and initiating DTG regimens.

methodsA two-year observational longitudinal cohort study conducted from 12th October 2020 to 31st December 2022. Fasting blood glucose was measured at baseline, 12, 24, 36 and 72 weeks for patients after a 12 h overnight fast. The Kaplan-Meier estimator was used to estimate the risk of developing type 2 diabetes mellitus (T2DM). Cox proportional hazard model was used in estimating hazard ratios.

resultsA total of 1334 non-diabetic patients were enrolled with 78% (1039) females and 83% (1104) were antiretroviral therapy experienced. The incidence proportion and rate of T2DM at 72 weeks were 11.8% (95%CI: 10.2-13.7) and 98.1 cases per 1000 PY (95%CI: 83.9-114.6) respectively. The median time to development of T2DM was 24 weeks post DTG initiation. Male sex (aHR 2.9 [95%CI: 1.9-4.3]), abnormal waist-hip ratio (1.67 [95% CI: 1.15-2.43]) and abnormal total serum cholesterol (aHR 1.6 [95%CI: 1.1-2.3]) were found to be significant determinants of T2DM.

conclusionIncidence of T2DM is high among non-diabetic PLHIV within 72 weeks of initiating DTG based therapy with males having a higher risk. Longitudinal changes in waist-hip ratio and serum cholesterol among patients initiated on DTG needs to be monitored regularly.

Indexed as

Diabetes Mellitus, Type 2Heterocyclic Compounds, 3-RingHIV InfectionsPiperazinesPyridonesAdultAnti-HIV AgentsBlood GlucoseDolutegravirFemaleGhanaHumansIncidenceLongitudinal StudiesMaleMiddle AgedAnti-HIV AgentsBlood GlucoseDolutegravirHeterocyclic Compounds, 3-RingOxazinesPiperazinesPyridonesARTCohort studiesDolutegravirSub-Saharan AfricaType 2 diabetes mellitus

Identifiers

PMID39614398
PMCPMC11607942

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.